Organon & Co Dossier - Source-backed chat

Organon & Co

OGNNYSE

SectorHealth Care

IndustryDrug Manufacturers - General

Beta (adjusted)1.35

Intrinsic Value $13.42median of 6 methods · middle span $4-$17based on filings through 30 Jun 2026

Market Price $13.71Price as of 1 Oct 2026

Near fair valueIntrinsic value is 2% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $3.6B

Enterprise Value $11B

Shares Outstanding 266.9M diluted

Moat Rating None

Next Earnings Date31 Jan 2027

Last ex-dividend14 Aug 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Organon & Co. (OGN) has transitioned from a fundamental standalone equity story to a binary merger arbitrage play following its definitive agreement on April 26, 2026, to be acquired by Sun Pharmaceutical Industries for $14.00 per share in cash. Standalone, Organon has struggled with a heavy debt burden (~$8.6 billion), high leverage (~4.3x net debt to adjusted EBITDA), and stagnant organic growth across its core Women's Health and Established Brands portfolios. The $11.75 billion enterprise value transaction represents a 103% premium to Organon's pre-rumor trading price and offers a clean exit for shareholders, effectively capping standalone downside while limiting further upside to the merger spread. A 'Hold' rating is maintained as the stock trades close to the deal price, reflecting high market confidence in completion but offering minimal standalone upside unless the transaction fails, which would trigger a severe downward re-rating.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$11.25

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$8.00

The acquisition by Sun Pharma fails due to unexpected regulatory/antitrust blockages or failure to secure shareholder approval. Standalone, Organon is forced to confront its $3.6 billion debt maturity wall in 2028 without a well-capitalized parent. The stock collapses back to its fundamental standalone valuation, driven by high leverage, declining legacy margins, and lack of near-term growth catalysts.

Base CaseCentral scenario

$11.25

Matches the consensus mean

The transaction proceeds along the expected timeline, closing in early 2027. Standalone operations remain flat in 2026, in line with management's guidance of flat revenue (~$6.2 billion) and adjusted EBITDA (~$1.9 billion). The stock trades tightly around the $13.40-$13.80 range, tracking the $14.00 cash deal price with a modest discount reflecting time value of money and minor regulatory risk.

Bull CaseUpside scenario

$14.00

The transaction closes smoothly on or ahead of schedule in early 2027. Regulatory clearances across global jurisdictions are obtained without major divestiture requirements, and Organon stockholders overwhelmingly approve the merger. Investors capture the remaining merger spread (~4-6% annualized depending on exact closing date) with minimal volatility.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Definitive all-cash acquisition agreement at $14.00 per share provides a guaranteed exit premium and resolves the company's long-standing debt overhang.
Strong underlying product economics with solid gross margins (~54%) and stable cash generation from established brands.
Entry of a highly capitalized parent (Sun Pharma) to absorb refinancing risks associated with the 2028 maturity wall.

Key Investment Risks

Binary deal risk: If the merger fails, the stock faces a sharp downward correction to pre-announcement levels (~$9.00 or lower).
Stagnant standalone organic growth and margin compression from loss of exclusivity on key legacy assets.
High leverage (net debt of ~$8.1 billion post-Jada divestiture) limits standalone capital allocation flexibility.

Thesis Invalidation Triggers

Official regulatory challenge or block of the Sun Pharma merger by antitrust authorities.
Public statements from major shareholder groups opposing the transaction terms.
Material adverse changes in Organon's core product portfolios (e.g., Nexplanon or biosimilars) that could trigger a material adverse effect clause in the merger agreement.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.